MEDVi vs Shed: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher & Publisher

Reviewed & updated August 14, 2026 · Cites primary sources (FDA, NEJM, CMS) · Not medical advice

54 providers verified independently·Independent research·How we rank →

Short answer: Shed scores higher on our rubric, 7.8/10 against 5.7/10. Full reasoning, pricing and the cases where the other one wins are below.

Visit Shed - our pick of these two →or find your match

Shed beats MEDVi overall, scoring 7.8/10 vs 5.7/10. Published pricing is not a like-for-like monthly comparison: MEDVi is $179 first month, then $299/mo; Shed is from $199/mo. Choose MEDVi for users who want both oral and injectable compounded options in one telehealth program. Choose Shed for users who want fast delivery and a streamlined compounded glp-1 experience.

A side-by-side look at MEDVi and Shed to help you decide. We compare them on:

•Starting price per month
•Our overall score, out of 10
•Medication type, brand-name or compounded
•Whether they accept insurance
•Who each one is best for

MEDVi

#46 of 54

5.7/10

MEDVi offers oral and injectable compounded GLP-1 care. Semaglutide is $179 for month one and $299 for refills. Trustpilot is 4.4/5 across roughly 11,000 reviews, while BBB is F/not accredited. FDA warning letter #721455 concerns misleading labeling and marketing, not an allegation that the medication was unsafe.

Visit MEDVi

Higher Rated

Shed

#12 of 54

7.8/10

Newer GLP-1 provider focused on speed and simplicity, fast approvals, fast shipping, and a clean user experience at a competitive price point.

Visit Shed

Feature	MEDVi	Shed
Why each one	Oral and injectable compounded formats in one program, with micro-dosing options and a path to FDA-approved brand medication.	The fastest GLP-1 delivery in the market, from signup to medication-in-hand in 2-3 days, with a streamlined experience that eliminates unnecessary friction.
Our Score	5.7/10	7.8/10
Headline Price	$179 first month, then $299/mo	from $199/mo
Medication Type	Both	Both
Insurance Accepted	No	No
Best For	Users who want both oral and injectable compounded options in one telehealth program	Users who want fast delivery and a streamlined compounded GLP-1 experience
Watch out for	FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing that implied MEDVi compounded the drugs and that compounded products were equivalent to or FDA-evaluated like approved brands. The letter does not allege unsafe medication	The core $199 program is compounded semaglutide and tirzepatide; brand-name access runs through a separate $99/mo pathway subscription with medication billed at pharmacy rates on top
Ranking	#46	#12
Get started	Visit MEDVi	Visit Shed

Pros & Cons Compared

MEDVi

Pros

+One of the few compounded providers offering both oral tablets and injectable semaglutide
+Micro-dosing options available, can start at sub-standard doses for patients concerned about side effects
+Sleek onboarding experience with clear progress tracking through their patient portal
+$179 covers the first month of compounded semaglutide on the current Katalys landing, including clinician review, medication and shipping

Cons

−FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing that implied MEDVi compounded the drugs and that compounded products were equivalent to or FDA-evaluated like approved brands. The letter does not allege unsafe medication
−Its third-party records conflict: 4.4/5 across roughly 11,000 Trustpilot reviews, but an F and no accreditation at the BBB
−The $179 semaglutide price is introductory; the current Katalys landing says refills are $299/mo, making the first-year total $3,468 rather than $2,148
−Brand-name Wegovy and Zepbound paths add a $99 membership plus the medication cost, which the current landing does not publish; availability can change
−No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms

Shed

Pros

+Industry-leading delivery speed, most patients receive medication within 2-3 days of enrollment
+$199/mo is competitively priced for an all-inclusive compounded program with good support
+Streamlined onboarding with no video call, approved and shipped faster than most competitors
+Clean, modern UX with real-time shipping tracking and easy provider messaging

Cons

−The core $199 program is compounded semaglutide and tirzepatide; brand-name access runs through a separate $99/mo pathway subscription with medication billed at pharmacy rates on top
−Newer company (founded 2024) with limited long-term track record and outcome data; the 4.6/5 Trustpilot rating across 766 reviews is the strongest early evidence available
−No insurance billing and no FSA/HSA superbills currently available
−Clinical support is responsive (replies typically within 24 hours) but less proactive than premium platforms; a $49.99/mo premium coaching add-on covers those who want higher touch

Our Verdict

Shed edges out MEDVi with a score of 7.8/10 vs 5.7/10. Published pricing is not a like-for-like monthly comparison: MEDVi is $179 first month, then $299/mo; Shed is from $199/mo.